Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsAntibody production from hybridoma does not conclude with the acquisition of antibodies, but rather with their efficient use in the experimental procedure and the achievement of desired experimental results. Consequently, after obtaining antibodies, hybridoma screening is often necessary to obtain target antibodies. For different experimental needs, Creative Biolabs offers comprehensive validation services to obtain function-guaranteed antibodies.
Immunohistochemical (IHC) technology is an assay that detects the presence of a target antigen in cells or tissues. It can be used not only to detect the expression of the antigen but also to observe the location of the antigen, allowing for qualitative, localization, and quantitative detection of the antigen. During the hybridoma screening process, the specificity, functional application, and stability of the antibody need to be further validated according to the specific IHC protocol.
Immunofluorescence (IF) technology is based on the principle of antigen-antibody reaction, in which fluorochromes that do not affect the activity of antigen and antibody are labeled on the antibody or antigen, and then combined with its corresponding antigen or antibody and observed under a fluorescent microscope to determine the nature and localization of the antigen or antibody. Immunofluorescence is detected by both direct and indirect methods. In order to obtain IF-positive antibodies after antibody production, we generally recommend additional antibody specificity verification and standard IHC testing to ascertain their functionality.
Western blotting (WB) technology is a method of transferring proteins to membranes and then using antibodies for qualitative and semi-quantitative detection. For known expressed proteins, the corresponding antibodies can be used as primary antibodies for detection, and for the expression products of new genes, antibodies to the fusion fraction can be used for detection.
Immunoprecipitation (IP) technology is a classical method for studying protein interactions, or interactions between proteins and genetic material, based on the specificity of the interaction between antibodies and antigens. It is an effective method for determining the physiological interactions between two proteins in intact cells and is one of the most widely used methods for antigen detection and purification. Using IP, the desired protein can be isolated from the sample, and the sample can then be separated by SDS-PAGE for WB analysis.
We recommend further antibody specificity testing as well as complete WB and IP testing to ensure the functionality of WB & IP positive antibodies.
Flow cytometry is used for counting and sorting tiny particles suspended in a fluid. This technique can be used to perform continuous multiparameter analysis of individual cells flowing through an optical or electronic detector. Fluorescence-activated cell sorting (FACS), which physically sorts cells into various containers using the properties measured in real time by flow cytometry, is one significant application. The method often uses immunophenotypic markers exposed on the cell surface, as antibodies can be used to label these markers while the cells are alive. Researchers often prefer to sort live cells in order to use isolated cell populations for subsequent experiments. FACS screening not only screens target hybridomas but also obtains FACS-positive hybridomas.
Enzyme-linked immunosorbent assay (ELISA) can be used to detect antibodies or antigens attached to a solid surface. It is one of the most commonly used laboratory-labeled immunoassay techniques and also one of the most sensitive immunoassays. Lateral flow immunochromatography assay (LFIA) has good applications in nucleic acid detection, such as coupled aptamer and specific nucleic acid sequence detection. In addition, it is increasingly used in disease diagnosis, drug monitoring, and food safety.
A highly specific and stable antibody is essential for ELISA and LFIA detection. Therefore, after obtaining antibodies using hybridomas, we need to perform further screening to obtain ELISA & LFIA-positive antibodies.
IHC-Positive Hybridoma Screening Introduction
IF-Positive Hybridoma Screening Introduction
WB & IP-Positive Hybridoma Screening Introduction
FACS-Positive Hybridoma Screening Introduction
ELISA & LFIA-Positive Hybridoma Screening Introduction
Creative Biolabs would like to share with you the key points and experience in obtaining function-guaranteed antibodies to facilitate your project.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
